In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus

At the onset of the 2013-2016 epidemic of Ebola virus disease (EVD), no vaccine or antiviral medication was approved for treatment. Therefore, considerable efforts were directed towards the concept of drug repurposing or repositioning. Amiodarone, an approved multi-ion channel blocker for the treatm...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2018-11, Vol.218 (suppl_5), p.S592-S596
Main Authors: Dyall, Julie, Johnson, Joshua C, Hart, Brit J, Postnikova, Elena, Cong, Yu, Zhou, Huanying, Gerhardt, Dawn M, Michelotti, Julia, Honko, Anna N, Kern, Steven, DeWald, Lisa Evans, O'Loughlin, Kathleen G, Green, Carol E, Mirsalis, Jon C, Bennett, Richard S, Olinger, Jr, Gene G, Jahrling, Peter B, Hensley, Lisa E
Format: Article
Language:English
Subjects:
Supplement
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:At the onset of the 2013-2016 epidemic of Ebola virus disease (EVD), no vaccine or antiviral medication was approved for treatment. Therefore, considerable efforts were directed towards the concept of drug repurposing or repositioning. Amiodarone, an approved multi-ion channel blocker for the treatment of cardiac arrhythmia, was reported to inhibit filovirus entry in vitro. Compassionate use of amiodarone in EVD patients indicated a possible survival benefit. In support of further clinical testing, we confirmed anti-Ebola virus activity of amiodarone in different cell types. Despite promising in vitro results, amiodarone failed to protect guinea pigs from a lethal dose of Ebola virus.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiy345